Talin1 modulates the Piezo1–YAP axis to regulate endothelial cell inflammation and atherosclerosis Authors: Yingzi Wang, Haozhong Huang, Zihao Liu, Zhenyu Gao, Bin Liao, Yang Long, Fengxu Yu, Yongmei Nie Published: 2025 ABSTRACT AbstractBackgroundAtherosclerosis is a chronic vascular inflammatory disease caused by multiple factors. Anti-inflammatory treatment is an effective approach to treat atherosclerosis. Talin1 is a cell membrane-associated cytoskeletal protein that is widely expressed in mammals and plays essential roles in angiogenesis and endothelial cell barrier function. However, the role of Talin1 in atherosclerosis and the related mechanisms remains unclear.MethodsApoE-KO mice were subjected to partial carotid artery ligation to establish an atherosclerosis model, and the expression of Talin1 in atherosclerotic plaques was verified in vivo. Human umbilical vein endothelial cells (HUVECs) and aortic endothelial cells (HAECs) were treated with tumour necrosis factor α (TNF-α) (10 ng/mL) and subjected to low oscillatory shear stress (OSS) (approximately ± 4 dyn/cm2) to establish cellular inflammation models. A lentivirus was used to regulate Talin1 expression in HUVECs and HAECs.ResultsTalin1 levels were increased in the serum of subjects with coronary heart disease (CHD) compared with those without CHD. We also found that Talin1 levels were increased in the serum of ApoE-KO mice in the operation group compared with the sham operation group. In addition, Talin1 expression was increased in endothelial cells in atherosclerotic plaques. In addition, neither TNF-α nor OSS promoted inflammation in endothelial cells with Talin1 knockdown. Moreover, we found that TNF-α and OSS could activate Piezo1 to mediate Ca²⁺ influx and subsequently activate Talin1 to regulate YAP and promote inflammation.ConclusionsThe results of this study suggest that Talin1 plays a vital role in endothelial inflammation and may be a novel anti-inflammatory therapeutic target for atherosclerosis.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00018-025-06026-8.Keywords: Talin1, Atherosclerosis, Inflammation, OSS, Endothelial cells Introduction Atherosclerosis is a multifactorial, chronic inflammatory vascular disease that underlies both acute coronary syndrome and ischaemic stroke [1]. Despite the success of statins and other lipid-lowering drugs in lowering cholesterol levels and treating cardiovascular diseases, atherosclerotic diseases such as acute coronary syndrome, ischaemic stroke, and myocardial infarction remain the leading causes of death worldwide. Therefore, other more effective therapeutic targets must be identified. An increasing number of studies have shown that inflammation is an essential component of the pathogenesis of atherosclerosis [2, 3]. Chronic inflammation in atherosclerotic lesions leads to fibrous caps and unstable plaques, which increase the incidence of adverse cardiovascular events [4]. In addition, omics analyses have shown that the vessels in atherosclerotic lesions are highly heterogeneous, which suggests the complexity of atherosclerotic inflammation [5–7]. In addition, large clinical trials have shown that the inhibition of vascular inflammation with canakinumab and colchicine reduces adverse cardiovascular events in patients with myocardial infarction compared with a placebo [8–10]. Therefore, identifying more precise and specific targets of inflammation and the targeted delivery of anti-inflammatory agents to atherosclerotic plaques may reduce the adverse effects of immunosuppression associated with high doses of anti-inflammatory agents [11, 12]. In conclusion, targeted anti-inflammatory treatment may be a novel and effective modality for atherosclerosis. Vascular endothelial cell homeostasis plays a crucial role in maintaining multiorgan homeostasis, and the disruption of vascular endothelial cell homeostasis is the initiating factor in atherosclerosis and a hallmark of many human panvascular diseases [13]. Endothelial dysfunction occurs when the cells lining blood vessels are chronically stimulated by various risk factors (hypertension, hyperlipidaemia, diabetes, and ageing, among others) [14]. When the vascular endothelium becomes dysfunctional and is affected by inflammation, it recruits circulating monocytes, which migrate to the subendothelium and differentiate into macrophages [14, 15]. Furthermore, damaged vascular endothelial cells have increased permeability to circulating LDL cholesterol, allowing it to be oxidized under the endothelial space and removed by macrophages to form foam cells [15]. This vicious cycle promotes the formation of atherosclerotic plaques. Second, vascular endothelial cells are regulated by haemodynamics and participate in pathophysiological progression in both health and disease. Flow patterns and haemodynamics vary according to the vessel geometry and velocity [16]. Uniform laminar shear stress was detected in the nonsusceptible parts of atherosclerotic lesions (the straight part of blood vessels). However, OSS was observed in regions prone to atherosclerosis (vascular tortuosity or bifurcation) [17, 18]. Laminar shear stress contributes to the homeostasis of endothelial cells. OSS disrupts endothelial cell homeostasis and promotes the development of atherosclerosis [13, 19]. The vascular endothelium is in direct contact with the blood in the vessel lumen and forms a protective barrier between the blood and the outer wall of the vessel. Vascular endothelial cells are regulated by a variety of mechanical forces but respond mainly to fluid shear stress [14, 20]. Vascular endothelial cells have many mechanoreceptors that sense blood flow shear stress and regulate the homeostasis of these cells. Mechanoreceptors are composed mainly of cell‒cell junction proteins, cell‒cell matrix adhesion molecules, receptors, and ion channels [21]. Among them, Talin1 is a mechanosensitive cell membrane-associated cytoskeletal protein that has attracted attention in recent studies on atherosclerosis. However, the underlying mechanism of Talin1 in atherosclerosis remains unclear. Therefore, clarifying the relationship between the mechanosensitive cytoskeletal protein Talin1 and vascular endothelial cell inflammation will help identify new anti-inflammatory targets for atherosclerosis. Talin1 is a mechanosensitive cell membrane-associated cytoskeletal protein (approximately 270 kDa) consisting of a rounded head structure (Talin-H), a rod domain (Talin-R), and a terminal dimer joining (DD) conformational domain [22–24]. Talin1 is expressed in almost all cells and plays a vital role in endothelial barrier function and angiogenesis [25, 26]. Previous studies have shown that the Talin1 level in the serum of patients with CHD is increased compared with that in patients without CHD and is correlated with the severity of coronary heart disease [27, 28]. However, the origin of Talin1 and the mechanism underlying its role in atherosclerosis have not been elucidated. On the one hand, some scholars have found that shear stress and low-density lipoprotein activate Talin1 to promote endothelial cell inflammation and the development of atherosclerosis [29]. On the other hand, the deletion of Talin1 in myeloid cells promoted the development of atherosclerosis. These findings suggest that Talin1 expression in different cells plays different roles in the development of atherosclerosis [30]. Moreover, miR-182-5p, miR-330-5p, and miR-9-5p have been shown to bind to the 3´-UTR of TLN1 to reduce Talin1 expression and lead to atherosclerotic plaque instability [31, 32]. These results suggest that Talin1 expression is dynamic and related to the stability of atherosclerotic plaques. Overall, Talin1 plays an essential role in the development of atherosclerosis and plays different roles in different cells and at various stages of atherosclerosis. However, the mechanism of Talin1 in atherosclerosis has not been fully elucidated. In this study, we first revealed that Talin1 expression was upregulated in endothelial cells in atherosclerotic plaques and that Talin1 knockdown in endothelial cells suppressed the expression of inflammatory molecules (VCAM1 and ICAM1). Second, Talin1 was regulated by intracellular calcium levels. When the intracellular calcium concentration decreased, Talin1 expression and endothelial cell inflammation were reduced. In addition, Talin1 knockdown in endothelial cells reduced the intracellular expression of YAP and inflammation. Our study improves our understanding of the mechanisms underlying the roles of Talin1 and endothelial cells in atherosclerosis. Methods Animal model All the animals were acclimated under standard laboratory conditions (ventilated room, 25 ± 1 °C, 60 ± 5% humidity, 12 h light/dark cycle) and had free access to water and food. All procedures were approved by the Experimental Animal Ethics Committee of Southwest Medical University (NO.:20240228-001). Operation group: 8-week-old ApoE-KO mice (Shanghai Model Organisms Center, China). The mice were anesthetized with 2%−3% isoflurane (RWD, R510-22-10), a ventral median incision (4–5 mm) was made in the neck, the left carotid artery was exposed, and the left external carotid artery, internal carotid artery, and occipital artery were ligated. The superior thyroid artery was preserved. Mice were monitored until postoperative awakening on a heating pad. The high-fat diet was continued for six weeks after the operation. Samples were harvested at 14 weeks of age. Sham group: 8-week-old ApoE-KO mice were anesthetized with 2%−3% isoflurane (RWD, R510-22-10), and a ventral median incision (4–5 mm) was made in the neck without ligation of the left carotid artery and its branches. Mice were monitored until postoperative awakening on a heating pad. The high-fat diet was continued for six weeks after the operation. Samples were taken after deep anesthesia with isoflurane at 14 weeks of age. Cell culture HUVECs and HAECs were obtained from ScienCell Research Laboratories. The item number of HUVECs is #8000. The item number of HAECs is #6100.HUVECs and HAECs were cultured in an extracellular matrix (ECM endothelial Cell medium, 1001) containing fetal bovine serum (FBS), penicillin, and streptomycin. The cells were cultured in a 5% CO2 incubator at 37 °C. The medium was changed every two days, and cells of passages 5 to 8 were used for experiments. On the one hand, in this study, cells were treated with TNF-α purchased from oncoprotein at a concentration of 10ng/mL. Endothelial cells were treated with TNF-α for four hours, and protein and RNA were extracted for subsequent experiments. On the other hand, in this study, a low oscillatory shear force of ± 4 dyn/cm2 was applied to the cells using the ibidi Pump System (Germany). The cells were seeded in µSlide I 0.4 Luer. After the cells were attached to the wall, the µSlide I 0.4 Ler was connected to Perfusion Set RED and then to the Fluidic Unit Quad (10904). After all the assembly was completed, the air bubbles were excluded, and the air tightness was detected without error. After completion of the experiment, cellular proteins were extracted and used for subsequent experiments. Lentiviral transfection: the lentiviruses used in this study were all sh-RNA, and the sh-Talin1 sequence was GCACTCACTGGAACCATTAAC. The sh-Piezo1 sequence was GGAUGUUCAACCAGAAUGUGGUGGC. Cells at the appropriate density were seeded in 6-cm Petri dishes and cultured at 37 °C for 16–24 h until the confluence of cells was about 70%. According to the instructions of the lentivirus (which was purchased from GENE, CHINA), an appropriate amount of lentivirus and HitransG A infection booster solution were added after the cells were changed in the medium. The cells were cultured for 16 h at 37 °C, then the medium was changed, and the culture was continued. Seventy-two hours after lentivirus transfection, the transfection efficiency was observed by fluorescence microscopy. Seventy-two hours after lentivirus transfection, stably transfected cell lines were established by adding Puromycin (0.5 µg) for 48 h and used for subsequent experiments. Western blot analysis The primary antibodies used for Western blot analysis were GAPDH (CST,2118 S), Talin1 (abcam, ab71333), Piezo1 (proteintech, 28511-1-AP), VCAM1 (abcam, ab134047), ICAM1 (abcam, ab282575), YAP (abcam, ab52771). Cells were washed twice with PBS after treatment and lysed for 30 min by adding protein lysate. The joint artery tissue of ApoE mice was added to the grinding strain, and the supernatant was collected. The cells were centrifuged at 12,000 rpm for 15 min at 4 °C, the supernatant was aspirated, and protein loading buffer (EpiZyme, LT101) was added, followed by boiling at 100 °C for 10 min. Proteins were separated by 8% SDS-PAGE (EpiZyme, PG211) (20 µg per well) and transferred to polyvinylidene fluoride membranes(Merck Millipore, IPVH00010, PVDF). Subsequently, PVDF membranes were blocked in 5% skim milk powder for 1 h, washed with TBST, and incubated with specific primary antibodies overnight at 4 °C. Secondly, the membranes were washed three times with TBST and incubated with secondary antibodies for one hour at room temperature and exposed. Western blots were quantified using ImageJ analysis software (NIH, Bethesda, MD, USA). Real-time quantitative polymerase chain reaction The list of primers used to amplify the indicated genes is as follows: Human Talin1: CTGGTACTGCGTCTGTGGTGAAC, GGTTGGAGGAGATTGTGGTGACTG; Human Piezo1: TCAGTGACAAGGTCAGCCCA, CACGAACTTGCCGATGACCA; Human VCAM1: TTCCTGCTCCGAAAATCCTGTG, TCCAGCCTGGTTAATTCCTTCAC; Human ICAM1: AAAGGATGGCACTTTCCCACTG, ACATTCACGGTCACCTTGCG. The relative mRNA expression levels of the above genes were detected by real-time fluorescence quantitative PCR. Total RNA was extracted from HUVEC and HAEC using TRIzol (Invitrogen, 15596026), and RNA purity was determined according to the absorbance ratio of 1.9–2.1 at 260–280 nm. The RNA amplification conditions for qPCR were as follows: First, the reaction was performed once at 95 °C for 5 min. Secondly, the reaction was repeated at 95℃ for 10 s and 60℃ for 30 s for 40 cycles. The CT value was calculated at the end of the response. Relative gene expression levels were analyzed using the 2−ΔΔCT method using GAPDH as the reference gene. Determination of calcium ion concentration Cells were seeded in 96-well plates and treated in groups. They were divided into control group, BAPT-AM (10 μm, MedChemExpress), EGTA (5mM, APExBIO), Yoda1 (5 μm, MCE) and Yoda1 + EGTA. The samples were washed twice with HBSS. A mixture of FLuo-4 (Solarbio, F8500-100 µg) and F127 (Solarbio, S7071-100 g) was prepared. The fluo-4 mixture was diluted according to the ratio of HBSS: flou-4 mixture = 400:2. The diluted fluo-4 mixture was added to a 96-well plate at 100ul per well. Incubate for 15 min. Absorbance was measured using a multifunctional microplate reader (excitation wavelength 494 nm, emission wavelength 516 nm) once per 70 s for 20 min. Immunofluorescence and immunochemistry Immunofluorescent molecular antibodies used CD31 (Abcam, ab76533), Talin1 (Abcam, ab71333), Piezo1 (Abclonal, A4340), VCAM1 (Abcam, ab134047), ICAM1 (Abcam, ab171123) and YAP (proteintech,66900-1-Ig). Mouse arterial tissues were removed and fixed with 4% paraformaldehyde. The plates were washed twice with PBS and then drilled with 0.2% Triton X-100 for 15 min. The cells were washed twice with PBS and blocked with goat serum for one hour at room temperature. It was washed twice with PBS and incubated with primary antibodies overnight at 4 °C. The plates were washed twice with PBS and incubated for 1 h at room temperature in the dark. The plates were washed twice with PBS and incubated for 15 min at room temperature in the dark with the addition of anti-fluorescence attenuation sealant containing DAPI. Fluorescence microscopy was used to take pictures and analyze the data. After the cells were seeded onto slides and processed, the medium was discarded and washed three times with PBST. Cells were then fixed with 4% paraformaldehyde for 15 min, punched with 0.5% Triton X-100 for 10 min, blocked with 5%BSA for one hour, washed three times with PBST, and incubated with primary antibodies overnight at 4 °C. PBST was washed three times, and the secondary antibodies were incubated in the dark for one hour at room temperature. PBST was washed three times, and cell slides were incubated for 5 min at room temperature in the dark by dropping anti-fluorescence attenuation sealant containing DAPI. A fluorescence microscope was used to take pictures in the dark to observe the protein expression. HE Mouse arterial tissues were collected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. The cells were stained with hematoxylin for 20 min and rinsed with running water for 2 min. The cells were differentiated with alcohol hydrochloride for 5 s and rinsed with running water for 2 min. Put into a weak alkaline solution at 50 °C to return to blue, and rinse with running water for 2 min. The cells were stained with eosin for 3 min, washed with running water for 5 s, and dehydrated with gradient alcohol. Immerse in xylene I for 3 min and xylene II for 5 min. The slices were sealed with a drop of tree-neutral glue and photographed under a microscope. Oil red O Mouse arterial tissues were collected, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. They were immersed in 60% isopropanol for 2 min and washed once with ice-distilled water. The modified oil Red O staining solution was incubated in the dark for 15 min and washed once with ice-distilled water. 60% isopropyl alcohol for 5 s and then washed once with ice distilled water. The cells were counterstained with a hematoxylin staining solution for 5 min and washed once with ice-distilled water. The slices were sealed with glycerin gelatin and photographed under a microscope. Enzyme-linked immunosorbent assay Blood samples were collected using EDTA-containing tubes, and eyeball blood was obtained from ApoE-KO mice. The supernatant was then removed by centrifugation at 3000 rpm for 30 min at 4 °C, and the plasma was frozen at −80 °C until analysis. According to the manufacturer’s instructions, Plasma Talin1 levels were measured using a Mouse Talin-1 (TLN1) ELISA Kit(MIbio, YJ254017, China). Acquisition of cell culture medium After the cells were treated with TNF-α for 4 h, the culture medium was collected. The medium was collected after the cells were treated with OSS for 4 h. The collected medium was centrifuged at 2000 rpm for 20 min at 4 °C to remove the supernatant and stored frozen at −80 °C until analysis. Medium Talin1 levels were measured using a kit (MM-63120H1) sold by MEIMIAN according to the manufacturer’s instructions. Statistical analysis All data from this experiment were analyzed and graphed using the statistical software GraphPad Prism 9.0. All quantitative data are presented as mean ± SEM. An unpaired t-test was used to compare the two groups, and an F-test was used to measure the homogeneity of variance. An unpaired t-test with Welch’s correction was used when variances were uneven. Statistical significance was as follows: no significance (n.s.); * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001. Each experiment was repeated at least three times independently. Result Talin1 expression is increased in endothelial cells in atherosclerotic plaques The expression of the cytoskeletal protein Talin1 is increased in serum from patients with CHD [27, 28]. However, the source of Talin1 and the mechanism of Talin1 in atherosclerosis remain unclear. First, 8-week-old ApoE-KO mice were subjected to partial ligation of the left carotid artery to establish an atherosclerosis model (Fig. 1A–B). The left and right common carotid arteries of the mice were stained with HE and oil red O, and the results showed apparent plaque formation in the left common carotid artery (Fig. 1C–D). Vascular endothelial cells are in direct contact with the blood; thus, they are prone to endothelial dysfunction and inflammation stimulated by various risk factors (hypertension, diabetes, and hyperlipidaemia) [13, 14, 16]. Damage to vascular endothelial cells is also among the initiating factors of atherosclerosis. The expression of Talin1 in atherosclerotic vascular endothelial cells was detected by costaining for CD31 (a vascular endothelial cell marker), VEGFR2 (vascular endothelial growth factor receptor 2), and Talin1. The results suggested that Talin1 expression was increased in the vascular endothelial cells of arteries with atherosclerotic plaques (LCA) compared with those of arteries without atherosclerotic plaque formation (RCA) (Fig. 1E–F). In addition, costaining for Talin1 and CD68 (a macrophage marker) was performed, and Talin1 expression was similarly increased in the LCA compared with the RCA (Fig. 1G). Second, proteins were extracted from the left and right common carotid arteries for Western blot analysis, and the results were consistent with the immunofluorescence staining. Talin1 expression was increased in atherosclerotic plaques (Fig. 1H). We also collected blood samples from the sham-operated group and the operation group for ELISA detection, and the results revealed that the Talin1 level in the serum of the operation group was higher than that in the serum of the sham-operated group (Fig. 1I). This finding is consistent with the results of previous studies [27, 28]. Vascular endothelial cells are essential factors that initiate the progression of atherosclerosis; therefore, this study focused on the role of Talin1 in the vascular endothelium. Talin1 expression is increased in atherosclerotic plaques. A: Schematic diagram of partial carotid artery ligation. AA: Aortic arch; ECA: External aorta; ICA: Internal carotid artery; OA: Occipital artery; STA: superior thyroid artery; B: Gross view of mice with partial carotid ligation; C: The LCA and RCA were stained with HE; D: Oil red O staining of the LCA and RCA; E: Talin1 and CD31 were fluorescently stained in the LCA and RCA;F: Talin1 and VEGFR were fluorescently stained in the LCA and RCA; G: Talin1 and CD68 were fluorescently stained in the LCA and RCA; H: Talin1 protein was expressed in the LCA and RCA; I: Expression of Talin1 in the serum of the sham-operated and operated groups; J: Talin1 was fluorescently stained with CD31 in the AA and TA. (n = 3;* P < 0.05;** P < 0.01;*** P < 0.001;**** P < 0.0001;Scale bar:20 μm,100 μm) Atherosclerosis occurs mainly at the bifurcation or tortuosity of the arterial opening and is less commonly observed in straight segments or downstream of the bifurcation [17, 18]. Studies have documented the existence of OSS at arterial opening bifurcations or tortuosity, and OSS is closely related to vascular endothelial damage in atherosclerosis [13, 19]. First, we examined Talin1 expression in the aortic arch (atherosclerotic susceptible zone) and thoracic aorta (atherosclerotic nonsusceptibility zone). Talin1 expression was higher in vascular endothelial cells in the AA than in those in the TA (Fig. 1 J). We next measured the expression of the marker molecule CD31 in HUVECs and HAECs to determine the cell type (Fig. 2A). OSS (± 4 dyn/cm2) was applied to HUVECs in vitro using an ibidi Pump System (Germany). OSS was applied to HUVECs for different durations. Talin1 expression was measured by Western blotting. The results suggested that Talin1 expression was most significantly increased at 4 h of OSS (Fig. 2B). Second, as early as the early 21 st century, monocytes and macrophages were shown to secrete TNF-α in vivo to promote the progression of inflammation and atherosclerosis, and increased levels of TNF-α are closely related to adverse cardiovascular events [33–35]. Furthermore, TNF-α is a critical modulator of the immune response in individuals with atherosclerosis [36]. Therefore, we also treated HUVECs and HAECs with TNF-α to establish cellular inflammation models. After 4 h of TNF-α treatment, immunofluorescence staining revealed that the expression of Talin1 increased in both HUVECs and HAECs (Fig. 2C–D). Moreover, the medium of endothelial cells stimulated with OSS and TNF-α was collected for ELISA. Talin1 levels were increased in the medium of cells subjected to OSS or treated with TNF-α compared with the levels in the medium of control cells (Fig. 2E). This finding is also consistent with the in vivo results in mice. In conclusion, based on these results, we conclude that Talin1 expression is upregulated in endothelial cells in atherosclerotic plaques. Talin1 expression is increased in endothelial cells of atherosclerotic plaques. A: Fluorescent staining of CD31 in HUVECs and HAECs; B: The expression of Talin1 changes with time in HUVECs stimulated by OSS; C: HUVECs were treated with TNF-α for immunofluorescence staining; D: HAECs were treated with TNF-α for immunofluorescence staining; E: Talin1 expression in the culture medium after stimulation of HUVECs and HAECs with TNF-α or OSS. (n = 3; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm) The depletion of Talin1 in endothelial cells inhibits inflammation Vascular endothelial cell homeostasis plays a positive role in maintaining normal vascular physiology, and the disruption of vascular endothelial cell homeostasis is the initial step in atherosclerosis. Many studies have shown that vascular endothelial cell inflammation plays a vital role in the development of atherosclerosis. As a mechanosensitive cytoskeletal protein, Talin1 has been shown to regulate endothelial cell barrier function by binding to integrins [26, 29]. However, few studies have investigated the role of Talin1 in endothelial cell inflammation. We knocked down Talin1 expression in HUVECs by lentivirus transfection. Second, we treated HUVECs with TNF-α and OSS and performed Western blot, quantitative real-time polymerase chain reaction, and immunofluorescence assays. The Western blot and quantitative real-time polymerase chain reaction results suggested that when Talin1 was knocked down in HUVECs, endothelial inflammation was not induced even in the presence of TNF-α or OSS. The expression of ICAM1 and VCAM1, inflammatory molecules, was also decreased in HUVECs (Fig. 3A–B, D). Immunofluorescence staining also revealed that under the same TNF-α stimulation conditions, Talin1 knockdown inhibited the expression of inflammatory molecules (ICAM1) in HUVECs compared with that in the control group (Fig. 3C). Knockdown of Talin1 in endothelial cells inhibits inflammation. A: TNF-α stimulated the expression of inflammatory molecules in HUVECs at the protein level after Talin1 knockdown; B: OSS stimulated the expression of inflammatory molecules in HUVECs after Talin1 knockdown at the protein level; C: ICAM1 expression in Talin1 knockdown HUVECs;D: TNF-α stimulated the expression of inflammatory molecules in HUVECs at the RNA level after Talin1 knockdown; E: TNF-α stimulated the expression of inflammatory molecules in HAECs at the protein level after Talin1 knockdown; F: OSS stimulated the expression of inflammatory molecules in HAECs after Talin1 knockdown at the protein level; G: ICAM1 expression in HAECs after Talin1 knockdown; H: TNF-α stimulated the expression of inflammatory molecules in HAECs at the RNA level after Talin1 knockdown. (n = 3; * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar: 100 μm) We subjected HAECs to the same treatment and obtained results consistent with what was observed in HUVECs. Talin1 was knocked down in HAECs, and these cells were treated with TNF-α or subjected to OSS. Talin1 knockdown suppressed inflammation in HAECs, as evidenced by changes in both the protein and RNA levels (Fig. 3E–F, H). The immunofluorescence staining results were consistent with those from the HUVECs (Fig. 3G). In summary, Talin1 knockdown in endothelial cells suppressed the expression of VCAM1, ICAM1, and inflammatory molecules in endothelial cells. This is beneficial for the maintenance of vascular endothelial cell homeostasis and inhibits inflammation and the development of atherosclerosis. In endothelial cells, Talin1 mediates cellular inflammation by regulating YAP YAP is a transcriptional coactivator that regulates endothelial cell inflammation, proliferation, and migration by binding to TEAD-DNA-binding protein [37]. In addition, Talin1 affects both the nuclear localization and transcriptional activity of YAP [38]. Both Talin1 and YAP have been shown to sense mechanical forces in atherosclerosis and renal cell carcinoma, but whether a regulatory relationship exists between Talin1 and YAP in atherosclerosis has not been elucidated. We first found that YAP expression increased after endothelial cells were treated with TNF-α (Fig. 4A, C). Second, lentivirus transfection was performed to knock down Talin1 expression in HUVECs, which were then stimulated with TNF-α and subjected to OSS. Western blotting and immunofluorescence staining were performed. The results suggested that when Talin1 expression was knocked down in HUVECs, the expression of YAP, VCAM1, and ICAM1 was also reduced (Figs. 3A–D and 4B and D–E). In addition, the same treatment was administered to HAECs before Western blot and immunofluorescence staining. Consistent with the results obtained from HUVECs, decreased Talin1 expression inhibited YAP, VCAM1, and ICAM1 expression in HAECs (Figs. 3E–G and 4F–H). Overall, we conclude that the activation of Talin1 further promotes YAP expression and inflammation when endothelial cells are stimulated with TNF-α and OSS. In endothelial cells, Talin1 mediates cellular inflammation by regulating YAP. A: The expression of Piezo1 and YAP changes after TNF-α stimulation of HUVECs; B: When Talin1 was knocked down and HUVECs was stimulated with TNF-α, the protein expression of YAP was decreased; C: The expression of Piezo1 and YAP changes after TNF-α stimulation of HAECs; D: When Talin1 was knocked down and HUVECs was stimulated with OSS, the protein expression of YAP was decreased; E: YAP expression after Talin1 knockdown in HUVECs; F-G: protein expression of YAP after Talin1 knockdown in HAECs; H: YAP expression after Talin1 knockdown in HAECs. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm) Piezo1 regulates inflammation via Talin1 in endothelial cells Piezo1 is a ubiquitously expressed mechanosensitive ion channel that plays important roles in vascular development and remodelling, flow-mediated activation of endothelial Ca²⁺ entry, and inflammatory signalling [21, 39–42]. In recent years, Piezo1 has been shown to mediate thrombosis and renal fibrosis by regulating Talin1 [43, 44]. Moreover, predictions using the STRING database revealed that Piezo1 and Talin1 may have a regulatory relationship (Fig. 5A). TNF-α and OSS increased Piezo1 expression in endothelial cells (Fig. 4A, C). We next knocked down Piezo1 expression in HUVECs by lentiviral transfection and treated them with TNF-α and subjected them to OSS. The Western blot results suggested that when Piezo1 was knocked down in HUVECs, the expression of Talin1 was also reduced, and the expression of inflammatory molecules (VCAM1 and ICAM1) was inhibited (Fig. 5B–C). In addition, the immunofluorescence results suggested that Piezo1 knockdown inhibited the expression of Talin1 and VCAM1 (Fig. 5D–E). In addition, we examined Piezo1 expression after Talin1 knockdown in HUVECs. The Western blot and immunofluorescence results showed that after Talin1 was knocked down in HUVECs, no significant change in Piezo1 expression was observed when the cells were stimulated with TNF-α or OSS (Fig. 5F–H). Piezo1 regulates inflammation through Talin1 in HUVECs. A: STRING network database predicted that Talin1 and Piezo1 may have a regulatory relationship; B-C: The protein expression of Talin1, VCAM1, and ICAM1 after knocking down Piezo1 in HUVECs; D: Talin1 expression after Piezo1 knockdown in HUVECs; E: VCAM1 expression after Piezo1 knockdown in HUVECs; F-H: Piezo1 expression after Talin1 knockdown in HUVECs. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm) We performed the same experiments in HAECs. The Western blot and immunofluorescence results were consistent with those obtained for HUVECs. Piezo1 knockdown inhibited Talin1 expression and further inhibited VCAM1 and ICAM1 expression (Fig. 6A–D). Second, after Talin1 was knocked down in HAECs, the expression of Piezo1 did not change significantly (Fig. 6E–G). Based on these results, we hypothesized that when endothelial cells are stimulated with TNF-α or OSS, the activation of Piezo1 further activates Talin1 to cause endothelial cell inflammation. Ca²⁺ can also regulate the expression of Talin1. Therefore, we wanted to explore whether Ca²⁺ in endothelial cells could mediate inflammation by regulating Talin1 expression. Piezo1 regulates inflammation through Talin1 in HAECs. A-B: The protein expression of Talin1, VCAM1, and ICAM1 after knocking down Piezo1 in HAECs; C: Talin1 expression after Piezo1 knockdown in HAECs; D: VCAM1 expression after Piezo1 knockdown in HAECs; E-G: Piezo1 expression after Talin1 knockdown in HAECs. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm) Decreases in intracellular calcium levels inhibit Talin1 expression and endothelial cell inflammation Intracellular calcium is a second messenger that is important in cellular physiology and pathology. However, calcium ions in the cytoplasm are derived mainly from extracellular and intracellular sources (the endoplasmic reticulum and sarcoplasmic reticulum) [45]. Moreover, elevated intracellular calcium concentrations promote cellular inflammation [46–48]. In addition, intracellular calcium regulates Talin1 expression in kidney disease [49–51]. However, few studies have investigated whether changes in the intracellular calcium concentration can regulate Talin1 expression and affect inflammation. Therefore, we first measured the intracellular Ca2+ concentration in HUVECs after treatment with an intracellular Ca2+ chelator (BAPT-AM, 10 μm) and an extracellular Ca2+ chelator (EGTA, 5 mM). The results showed a decrease in the intracellular calcium concentration (Fig. 7A). Second, we treated HUVECs simultaneously with TNF-α and BAPT-AM and performed Western blot analyses. The results suggested that the expression of Talin1, VCAM1, and ICAM1 decreased when an intracellular calcium chelator was administered to chelate the intracellular calcium ions and when TNF-α was used to stimulate cellular inflammation (Fig. 7B). Reduced Ca²⁺ concentration inhibits Talin1 and inflammation in HUVECs A: The intracellular calcium concentration of HUVECs treated with calcium chelator; B: Protein expression of Talin1, VCAM1, and ICAM1 in HUVECs treated with BAPT-AM; C: Expression of Talin1 and ICAM1 in HUVECs treated with BAPT-AM; D: RNA expression of Talin1, VCAM1, and ICAM1 in HUVECs treated with BAPT-AM; E: Protein expression of Talin1, VCAM1, and ICAM1 after EGTA treatment of HUVECs; F: Talin1 and ICAM1 expression after EGTA treatment of HUVECs; G: RNA expression of Talin1, VCAM1, and ICAM1 in HUVECs treated with EGTA. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm.) Immunofluorescence staining showed that the expression of Talin1 and ICAM1 decreased when the concentration of intracellular calcium ions decreased (Fig. 7C). However, the quantitative real-time polymerase chain reaction results suggested that the reduction in the intracellular calcium ion concentration could not inhibit the expression of Talin1 at the RNA level (Fig. 7D). In addition, we treated HUVECs with an extracellular calcium chelator and TNF-α and performed Western blot analyses. These results were consistent with those obtained for cells treated with intracellular calcium chelators, and the expression of Talin1, VCAM1, and ICAM1 decreased (Fig. 7E). Immunofluorescence staining was also performed, and the results showed that the expression of Talin1 and ICAM1 was also downregulated when the concentration of intracellular calcium ions decreased (Fig. 7F). The quantitative real-time polymerase chain reaction results also indicated that a reduction in the intracellular calcium ion concentration could not inhibit Talin1 expression at the RNA level (Fig. 7G). We performed the same experiments using HAECs. The Western blot and immunofluorescence results were also consistent with those obtained using HUVECs, and a decreased intracellular calcium concentration inhibited the expression of Talin1, VCAM1, and ICAM1 (Fig. 8A–C, E-F). Quantitative real-time polymerase chain reaction also revealed that a reduction in the intracellular calcium ion concentration did not inhibit Talin1 expression at the RNA level (Fig. 8D, G). Taken together, these findings suggest that the intracellular calcium ion concentration regulates Talin1 expression at the protein level to regulate inflammation. Reduced Ca²⁺ concentration inhibits Talin1 and inflammation in HAECs A: The intracellular calcium concentration of HAECs treated with calcium chelator; B: Protein expression of Talin1, VCAM1, and ICAM1 in HAECs treated with BAPT-AM; C: Expression of Talin1 and ICAM1 in HAECs treated with BAPT-AM; D: RNA expression of Talin1, VCAM1, and ICAM1 in HAECs treated with BAPT-AM; E: Protein expression of Talin1, VCAM1, and ICAM1 in HAECs treated with EGTA; F: Talin1 and ICAM1 expression in HAECs after EGTA treatment; G: RNA expression of Talin1, VCAM1, and ICAM1 after EGTA treatment of HAECs. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; Scale bar:100 μm) Piezo1 regulates the expression of Talin1 through calcium ions to regulate inflammation in endothelial cells Based on the aforementioned results, we concluded that Piezo1 and Ca²⁺ could regulate Talin1 expression to mediate endothelial cell inflammation. Therefore, we wondered whether Piezo1 could mediate Talin1 and cellular inflammation by regulating intracellular Ca²⁺ levels. We first treated HUVECs with a Piezo1-specific agonist (Yoda1, 5 μm) and EGTA and measured the intracellular Ca²⁺ concentration. Compared with Yoda1 alone, Yoda1 and EGTA reduced the intracellular calcium concentration (Fig. 9A). Second, we performed lentivirus transfection to knock down Piezo1 in HUVECs and determined the intracellular calcium ion concentration, and the results also revealed that compared with the level in the NC group, the intracellular calcium ion concentration decreased after Piezo1 was knocked down (Fig. 9A). We performed the same treatment in HAECs, and the results were consistent with those in HUVECs. Treatment of HAECs with Yoda1 and EGTA or knockdown of Piezo1 with a lentivirus changed the intracellular Ca²⁺ concentration (Fig. 9B). In endothelial cells, Piezo1 regulates the expression of Talin1 through calcium ions to regulate cell inflammation A: Umbilical vein intracellular calcium concentrations were measured after HUVECs were treated with Yoda1 and EGTA or after Piezo1 knockdown using lentivirus in HUVECs; B: HAECs were treated with Yoda1 and EGTA, and the intracellular calcium concentration was measured after Piezo1 knockdown by lentivirus; C: Piezo1, Talin1, VCAM1, and ICAM1 protein expressions were detected after the knockdown of Piezo1 by TNF-α, BAPT-AM, and lentivirus in HUVECs; D: The protein expression of Piezo1, Talin1, VCAM1, and ICAM1 was detected after the knockdown of Piezo1 by TNF-α, BAPT-AM, and lentivirus in HAECs; E: The expression levels of Talin1, inflammatory molecules and the calpain family changed at the RNA level, after OSS and BAPT-AM stimulated HUVECs; F: The expression levels of Talin1 and inflammatory molecules changed at WB, after OSS and BAPT-AM stimulated HUVECs; G: The expression levels of Talin1, inflammatory molecules and the calpain family changed at the RNA level, after OSS and sh-Talin1 stimulated HUVECs. (n = 3; no significance (n.s.), * P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001) Next, we used a lentivirus to knockdown Piezo1 in HUVECs and treated the cells with TNF-ɑ and BAPT-AM and then measured the expression of Piezo1, Talin1, VCAM1, and ICAM1. The Western blot results showed that BAPT-AM did not affect the expression of the Piezo1 protein. Compared with Piezo1 knockdown alone, BAPT-AM combined with Piezo1 knockdown further reduced the expression of Talin1, VCAM1, and ICAM1 (Fig. 9C). We performed the same treatment on HAECs, and the results were consistent with those obtained using HUVECs (Fig. 9D). Therefore, we continued to explore whether a Ca2+-binding protein interacts with Talin1. Talin1 is composed of Talin1-H, Talin1-R, and a nonstructural linker of 80 amino acids. Two active states of Talin1 have been identified in cells: one is the autoinhibitory state, where Talin1-H and Talin1-R are interconnected; the other is the active state, where Talin1-H and Talin1-R are separated from each other, and Talin1 is in an extended conformation. The binding sites of various proteins are located on Talin1-H and Talin1-R. When Talin1 is active, its binding to different proteins results in a different domain unfolding order, which affects subsequent signal transduction and phenotypic changes. Talin1 is modified by proteolytic cleavage by calpain, which is mechanistically sensitive and affects subsequent signalling and the phenotype. However, calpain has a different isoform, and less is known about the binding of Talin1 to that isoform. We therefore treated HUVECs with OSS and BAPT-AM and evaluated the expression of Talin1, inflammatory molecules, and four isoforms of the calpain family. The results suggested that when HUVECs were subjected to OSS, the expression of calpain 1, calpain 3, and calpain 4 did not significantly change in the model group treated with BAPT-AM, whereas the expression of calpain 2 increased to a certain extent, and the expression of inflammatory molecules decreased compared with the levels in the model group that was not treated with BAPT-AM (Fig. 9E–F). On the other hand, we treated HUVECs with OSS and a sh-Talin1 lentivirus and similarly examined the expression of Talin1, inflammatory molecules, and four isoforms of the calpain family. The results suggested that when HUVECs were stimulated with OSS, the expression of Talin1 and inflammatory molecules in the model group transfected with sh-Talin1 decreased, while the expression of the four subtypes of the calpain family did not change significantly compared with those in the model group without sh-Talin1. Overall, we hypothesized that when endothelial cells are stimulated with TNF-α or OSS, Piezo1 is first activated to induce Ca²⁺ influx, after which Ca²⁺ binds to calpain 2 and subsequently activates Talin1, ultimately contributing to the inflammatory response of endothelial cells. Discussion Atherosclerosis is a chronic arterial inflammatory disease that is associated with multiple inflammatory pathways, such as the NLRP3 and Notch signalling pathways [3]. Clinical alleviation of atherosclerosis and its complications have been achieved mainly through lipid-lowering therapy, vascular reconstruction technology, and prevention strategies [12]. However, the mortality rate of adverse cardiovascular events continues to increase, which has prompted us to search for new targets for the treatment of atherosclerosis [52]. Because inflammation is an integral part of the progression of atherosclerotic disease, an increasing number of studies have been conducted in recent years to identify new therapeutic targets for atherosclerosis from the perspective of inflammation. Moreover, large clinical trials have shown that anti-inflammatory drugs can reduce the incidence of adverse cardiovascular events, and the targeted delivery of anti-inflammatory medications to atherosclerotic plaques is highly important for the timing of cardiovascular inflammation treatment and for reducing adverse reactions to the systemic use of anti-inflammatory drugs [11, 12, 53]. Therefore, identifying more specific markers of vascular inflammation will facilitate the treatment of atherosclerosis and reduce the incidence of adverse cardiovascular events. Piezo1 is a mechanosensitive cation channel that mediates calcium influx and the activation of inflammatory signalling. Many studies have demonstrated that Piezo1 promotes atherosclerosis by mediating endothelial cell inflammation and macrophage pyroptosis [54–56]. Studies have also shown that Piezo1 mediates thrombosis and renal fibrosis by regulating Talin1 [43, 44], and a regulatory relationship between Piezo1 and Talin1 has been predicted by STRING. We also revealed that TNF-α stimulation of endothelial cells activated Piezo1, which further activated Talin1 to promote endothelial inflammation. In addition, Ca²⁺ regulation of Talin1 expression has been observed in kidney diseases [46–48]. Our study also showed that Piezo1 could induce endothelial cell inflammation by mediating Ca²⁺ influx and subsequently activating Talin1. In summary, Piezo1 is an essential component for inflammation in atherosclerosis, and calcium is an intracellular second messenger and a vital component in cellular inflammation. Talin1, which is downstream of Piezo1 and calcium, also plays an essential role in the occurrence of endothelial cell inflammation. Therefore, blocking Talin1 can inhibit Piezo1- and intracellular calcium-induced cellular inflammation, and Talin1 can be detected in serum, suggesting that Talin1 may help determine the characteristics of atherosclerotic inflammation and the timing of atherosclerosis treatment. However, the mechanism of Talin1 in the development of atherosclerosis has not been fully elucidated, and further studies are needed. Interestingly, Piezo1 was also shown to differentially regulate the dynamics of specific integrin isoforms, which are heterodimeric receptors consisting of α and β subunits that play a critical role in mechanotransduction processes affecting cell differentiation, development, and cancer, as well as serving as an essential binding protein for Talin1 [57].The transition process of an integrin from a low-affinity ligand-binding state to a high-affinity ligand-binding state is called integrin activation. There are two main mechanisms for integrin activation: Talin1-dependent and direct activation by mechanical force. Firstly, there are two NPXY sites in the cytoplasmic domain of the integrin βsubunit. The proximal membrane NPXY site (NPLF in β2) is the Talin1 binding site, and the distal membrane NPXY site (NPKF in β2) is the kindlin binding site [58]. Talin1 could directly bind to the NPXY site of the integrin β subunit and activate integrin. Talin1 can also first form a Talin1 dimer through the talin1-DD domain, talin1-h binds to integrin i1, and talin1-R is linked to kindlin that binds to another integrin i2 via paxillin, and Talin1 is also bound to the β subunit of integrin i2. This talin-paxillin-kindlin junction enhances talin1 dimer-induced integrin microaggregation, leading to efficient multivalent binding of integrins and efficient FA assembly, thereby promoting cell adhesion [58, 59]. Next, a certain degree of mechanical force can also activate integrins, and relatively low forces (1 to 3 pN) are sufficient to stabilize the high-affinity ligand binding state of integrins. Extracellular matrix stiffness can also regulate Piezo1 activation in an integrin isoform-dependent manner [60]. Different extracellular matrices can alter the duration of Piezo1 activation and the response time to shear. Studies have shown that blocking specific isoforms of integrins (namely α4, α5, and β1) can prevent Piezo1-induced cell adhesion and downstream calpain/PKC signaling during erythropoiesis [61]. Moreover, Talin1-dependent integrin β1 activation in vascular endothelial cells can stabilize VE-cadherin at the vascular endothelial junction, promoting endothelial barrier function [26]. In summary, Talin1, a common downstream molecule of Piezo1 and integrin, plays a crucial role in the progression of atherosclerosis. Further exploration of the potential molecular mechanisms of Talin1, Piezo1, and integrin will aid in the development of treatments for atherosclerosis. The Hippo signalling pathway is also mechanosensitive and plays a vital role in endothelial cell proliferation and inflammation. YAP is a crucial component of the Hippo signalling pathway and a transcriptional coactivator. Our study revealed that when endothelial cells were stimulated with TNF-α, Talin1 activation regulated YAP expression and promoted inflammation in endothelial cells. Although few studies have investigated the regulation of YAP by Talin1, Talin1 knockdown or the disruption of Talin1 binding to vinculin has been shown to inhibit the nuclear localization and transcriptional activity of YAP [38]. Vinculin is also a cytoskeletal protein that plays a role in atherosclerosis by regulating the endothelial cell barrier. Like Talin1, it is also detected in the serum of patients with CHD [62, 63]. While our study demonstrated that Talin1 regulates YAP expression to promote endothelial cell inflammation, other studies have shown that a reduction in Talin1 expression or the disruption of Talin1 binding to vinculin affects YAP nuclear localization and transcriptional activity. However, the regulatory roles of Talin1, Vinculin, and YAP in atherosclerosis have not been elucidated. Moreover, Talin1 and Vinculin can be detected in the serum of patients with coronary heart disease; however, whether Talin1 and Vinculin can be used to predict atherosclerotic vascular inflammation and plaque stability, and their regulatory relationship in atherosclerotic plaques has not been elucidated. More research is needed to clarify these aspects. As mentioned above, chronic inflammation and low oscillatory shear stress play essential roles in the progression of atherosclerosis, and extensive clinical trials have confirmed that anti-inflammatory treatment reduces the incidence of adverse cardiovascular events [11, 12, 53]. However, specific targeted anti-inflammatory markers are lacking. Specifically, targeted anti-inflammatory markers can not only help reduce the incidence of adverse cardiovascular events but also help reduce adverse reactions to the systemic use of anti-inflammatory drugs. Talin1, a mechanosensitive cytoskeletal protein, was shown to be closely related to endothelial cell inflammation in the present study. It has been demonstrated that talin1 is required for integrin β3 to suppress the production of inflammatory cytokines by macrophages, thereby contributing to the development of atherosclerotic disease [30]. Thus, intact monocyte recruitment and elevated inflammatory responses lead to worsening of atherosclerosis in Talin1-deficient mice. However, few studies have investigated the anti-inflammatory activity of Talin1 in atherosclerosis. In the future, the relationship between Talin1 and targeted anti-inflammatory agents in atherosclerosis should be explored from two aspects. Talin1 expression is increased in the serum of individuals with atherosclerosis and is associated with atherosclerotic plaque stability, but the relationship between Talin1 expression and plaque stability is still unclear [31, 32, 64, 65]. Therefore, serum Talin1 expression may be used to detect the stability of atherosclerotic plaques and reduce the incidence of adverse cardiovascular events in the future. On the other hand, cyanidin-3-glucoside, as the main active component of anthocyanins, has been shown to not only protect the vascular endothelium and delay the progression of atherosclerosis through anti-inflammatory and antioxidant mechanisms but also mediate the treatment of colon cancer by inhibiting integrin activation through binding to Talin1 [32, 66, 67].In addition, studies have shown that C3G can inhibit the apoptosis and inflammation of vascular endothelial cells by regulating the miR-204-5p/SIRT1 axis, thereby alleviating atherosclerosis [68]. Non-coding RNAs(miR-182-5p and miR-9-5p) also regulate the expression of Talin1 in CHD [31, 64]. Therefore, studies have shown that C3G may regulate Talin1 through a non-coding RNA, thereby affecting atherosclerosis. However, the relationships among Talin1, cyanidin-3-glucoside, and inflammation in atherosclerosis have not been proven, and more studies are needed to clarify these relationships. Talin1 may be a target of cyanidin-3-glucoside in the treatment of atherosclerotic inflammation. In summary, Talin1 may be a potential therapeutic target for atherosclerosis, but more studies are needed to clarify the mechanism of Talin1 in atherosclerosis. Taken together, these findings suggest that TNF-α stimulation of endothelial cells first activates Piezo1 to mediate Ca²⁺ influx and then activates Talin1 to regulate YAP expression and ultimately promote endothelial cell inflammation (Fig. 10). Talin1 in endothelial cells is expected to be a new anti-inflammatory target for atherosclerosis. TNF-α and OSS stimulation of endothelial cells first activate Piezo1 to mediate Ca²⁺ influx and then activate Talin1 to regulate YAP and ultimately promote endothelial cell inflammation Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 (PPTX 1.03 MB) Supplementary Material 2 PPTX 63.5 MB) Acknowledgements Not applicable. Abbreviations Aortic arch Bovine serum albumin Coronary heart disease Deoxyribonucleic acid Ethylene Diamine Tetraacetic Acid External aorta Endothelial cell culture medium Fetal bovine serum Human Umbilical Vein Endothelial Cell Human aortic endothelial cells Internal carotid artery Intercellular adhesion molecule-1 Left common carotid artery Negative control Occipital artery Low oscillatory shear force Polyvinylidene fluoride membranes Phosphate Buffer solution Partial carotid artery ligation group Ribonucleic acid Right common carotid artery Superior thyroid artery Sham operation group Thoracic aorta Tumor necrosis factor α Triethanolamine buffered saline solution Vascular cell adhesion molecule-1 Author contributions Yingzi Wang: Conceptualization, Writing- Original Draft, Visualization, Data Curation; Haozhong Huang: Writing-Review & Editing, Data Curation; Zihao Liu: Writing-Review & Editing; Zhenyu Gao: Data Curation; Bin Liao: Resources, Project administration; Yang Long: Project administration; Fengxu Yu: Project administration, Funding acquisition; Yongmei Nie: Supervision, Project administration, Funding acquisition. All authors read and approved the final manuscript. Funding This work is supported by the 2022 Sichuan Province Science and Technology Plan joint innovation project(No.: 2022YFS0617 and No.: 2022YFS0610), Luzhou Municipal People’s Government - Southwest Medical University Science and Technology Strategic Cooperation Project (No.:2021LZXNYD-Z07 and No.: 2021LZXNYD-J26) and The Key Laboratory of Medical Electrophysiology, Ministry of Education, Open Fund༈No: KeyME- 2023-01. Data availability Data sharing does not apply to this article as no datasets were generated or analyzed during the current study. In this study, we used the STRING database, available at https://cn.string-db.org/. Its use by non-academic staff is not restricted. Declarations Ethics approval and consent to participate On February 28, 2024, animal ethics was approved by the Experimental Animal Ethics Committee of Southwest Medical University (approval no. 20240228-001). All experimental procedures involving animals were performed by the methods approved by the Experimental Animal Ethics Committee of Southwest Medical University. The Experimental Animal Ethics Committee of Southwest Medical University follows the rules of the Basel Declaration. Consent for publication All the authors have approved the manuscript. Authors' information (optional) Not applicable. Clinical trial number Not applicable. This manuscript does not contain any studies conducted on human participants by any of the authors. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Fengxu Yu, Email: yuluchuan@163.com. Yongmei Nie, Email: nieyongmei@126.com. References Associated Data Supplementary Materials Supplementary Material 1 (PPTX 1.03 MB) Supplementary Material 2 PPTX 63.5 MB) Data Availability Statement Data sharing does not apply to this article as no datasets were generated or analyzed during the current study. In this study, we used the STRING database, available at https://cn.string-db.org/. Its use by non-academic staff is not restricted.